On December 11, 2015 Eleison Pharmaceuticals LLC, a specialty pharmaceutical company developing life-saving therapeutics for rare cancers reported the issuance of United States Patents, No. 9,205,098 and No. 9,107,824 (Press release, Eleison Pharmaceuticals, NOV 12, 2015, View Source [SID1234517396]). No. 9,205,098 describes the treatment of cancer patients with the combination of chemotherapeutic agents Glufosfamide and gemcitabine. No. 9,107,824 describes the method and use of ILC (lipid-complexed cisplatin), via intraperitoneal administration, for the treatment of patients with cancer, such as ovarian cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!